Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PCSK9 | Q8NBP7 | 12/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248528 | 0.81 | HCAR3 (0.46) | MEN1ALDH1A1HTTKMT2AL3MBTL1 | |
| SCHEMBL23845465 | 0.79 | KDM4E (0.41) | MEN1ALDH1A1HTTKMT2AL3MBTL1 | |
| SCHEMBL4245305 | 0.72 | MEN1 (0.42) | MEN1ALDH1A1HTTKMT2AL3MBTL1 | |
| SCHEMBL13740956 | 0.72 | ALDH1A1 (0.42) | MEN1ALDH1A1HTTKMT2AL3MBTL1 | |
| SCHEMBL24616542 | 0.71 | HCAR3 (0.53) | MEN1ALDH1A1HTTKMT2AKDM4E | |
| SCHEMBL19151378 | 0.70 | ADORA3 (0.53) | MEN1ALDH1A1HTTKMT2AL3MBTL1 | |
| SCHEMBL2894259 | 0.69 | — | — | |
| SCHEMBL3602693 | 0.69 | ALDH1A1 (0.34) | ALDH1A1L3MBTL1KDM4ENPC1RAB9A | |
| SCHEMBL5923892 | 0.68 | RAB9A (0.56) | MEN1ALDH1A1HTTKMT2AKDM4E | |
| SCHEMBL19153944 | 0.68 | SMN1; SMN2 (0.55) | ALDH1A1L3MBTL1KDM4ELMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| EP-1869016-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006095159-A1 | (IMIDAZOLO-5-YL)-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233928-A1 | IMIDAZOLO-5-YL-2-ANILO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | MKI67, TYMP, PCNA | MEN1 1784/4885ALDH1A1 466/4885HTT 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.